TD Cowen analyst Brendan Smith reiterated a Buy rating on Arrowhead Pharma (NASDAQ: ARWR).The analyst commented, "ARWR's Cardiometabolic R&D Day ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE